Teleflex Inc (TFX) Stock Price & Analysis
Teleflex Inc (TFX) rose 0.72% to USD 132.1 as of July 25, 2026 at 01:44 UTC, according to Nexqual real-time market data.
TFX last closed at USD 131.16; the session ranged USD 130.95–133.58 on volume of 232,874 shares. Market capitalization is —, with a 52-week range of USD 100.18–139.67 (NYQ). Source: Nexqual, July 25, 2026 at 01:44 UTC.
Key Statistics (as of July 25, 2026 at 01:44 UTC)
| Price | USD 132.1 |
|---|---|
| Change | ▲ 0.72% (up) |
| Previous Close | USD 131.16 |
| Open | USD 131.24 |
| Day Range | USD 130.95 – 133.58 |
| 52-Week Range | USD 100.18 – 139.67 |
| Volume | 232,874 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (TFX)
Nexqual's technical model rates TFX "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 01:44 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 49.66 (neutral) |
| vs SMA50 | Above (USD 130.74) |
| MACD | 1.03 (positive) |
Analyst Ratings (TFX)
Wall Street analysts rate TFX "Buy" based on 10 analysts, with a mean price target of USD 147.7 (range USD 135–160), per Nexqual as of July 25, 2026 at 01:44 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 147.7 |
| High Target | USD 160 |
| Low Target | USD 135 |
| Buy / Hold / Sell | 5 / 7 / 0 |
Earnings (TFX)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 1.27 |
| Revenue Estimate | $559.02M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.39 vs est 1.21 ▲ beat |
| 2025-12-31 | USD 1.93 vs est 3.75 ▼ miss |
| 2025-09-30 | USD 3.67 vs est 3.38 ▲ beat |
| 2025-06-30 | USD 3.73 vs est 3.37 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:44 UTC.
Financials & Fundamentals (TFX)
| Total Revenue | $2.13B |
|---|---|
| Revenue Growth (YoY) | +32.30% |
| Gross Margin | +55.33% |
| Operating Margin | +8.36% |
| Profit Margin | -47.43% |
| ROE | +0.04% |
| Debt / Equity | 88.79 |
| Current Ratio | 2.55 |
| Total Cash | $333.06M |
| Total Debt | $2.74B |
| Free Cash Flow | $-3.68M |
Source: Nexqual, July 25, 2026 at 01:44 UTC.
Financial Health Score (TFX)
Nexqual rates Teleflex Inc's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 01:44 UTC.
| Growth | Strong — Revenue +32% YoY (latest Q) |
|---|---|
| Profitability | Strong — Gross margin 55%, operating 8% |
| Balance Sheet | Mixed — $333M cash vs $2.74B debt |
| Cash Flow | Weak — FCF negative: -$4M, burning cash |
| Efficiency | Weak — ROE 0%, ROA 2.3% |
Ownership (TFX)
| Insider Ownership | +0.47% |
|---|---|
| Institutional Ownership | +109.25% |
| Float | 44.11M |
| Short % of Float | +8.52% |
Source: Nexqual, July 25, 2026 at 01:44 UTC.
Leadership (TFX)
Teleflex Inc is led by Jason Weidman, President, CEO & Director, per Nexqual as of July 25, 2026 at 01:44 UTC.
| President, CEO & Director | Jason Weidman |
|---|---|
| Executive VP & CFO | John R. Deren (age 57) |
| Corporate Vice President of Human Resources & Communications | Cameron P. Hicks (age 60) |
| Vice President of Investor Relations & Strategy Development | Lawrence Soren Keusch |
| Vice President of Corporate Development | Matt Tomkin |
Major Backers & Investors (TFX)
Notable institutional backers of Teleflex Inc include T. Rowe Price, Janus Henderson Group PLC, JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund, according to Nexqual as of July 25, 2026 at 01:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| T. Rowe Price | 12.78% |
| Janus Henderson Group PLC | 9.69% |
| JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund | 6.52% |
| BAUPOST GROUP LLC/MA | 3.6% |
| Sessa Capital IM, L.P. | 3.45% |
| Fuller & Thaler Asset Management Inc. | 3.08% |
| Citadel | 2.65% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 18.24% |
| Vanguard Group | 18.05% |
| State Street | 3.39% |
Source: Nexqual, July 25, 2026 at 01:44 UTC.
From Teleflex Inc's Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally.
- It also provides interventional products, including various coronary catheters, structural heart support devices, and peripheral intervention products platforms; GuideLiner, Turnpike, and TrapLiner catheters; MANTA vascular closure devices and Arrow OnControl powered bone biopsy systems; and coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters.
- In addition, the company offers surgical products, including metal and polymer ligating clips using manual and automatic applier system, fascial closure surgical systems used in laparoscopic surgical procedures, percutaneous surgical systems, powered bariatric staplers, and other surgical instruments under the Weck, MiniLap, Pleur-Evac, Deknatel, KMedic, Pilling, and Titan SGS brands.
- It serves hospitals, healthcare providers, and medical device manufacturers.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| STE | STERIS plc (Ireland) | USD 214.07 | ▲ 1.66% |
| COO | The Cooper Companies, Inc. | USD 70.31 | ▼ 0.27% |
| MTD | Mettler-Toledo International, I | USD 1,327.18 | ▲ 3.21% |
| IEX | IDEX Corporation | USD 223.27 | ▲ 0.05% |
| WST | West Pharmaceutical Services, I | USD 328.2 | ▼ 8.43% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:44 UTC. This page is informational and not investment advice.